Abstract
The adapter protein β-arrestin2 inhibits Mrgprb2 and FcεRI-mediated mast cell degranulation to attenuate pseudo-allergy and anaphylaxis. Thus, targeting β-arrestin2 in mast cells could provide novel therapeutic options for modulating pseudo-allergy and anaphylaxis.